Study endpoints
death, cardiac death, chest pain, myocardial necrosis, angina pectoris, AKI, non-cardiac death, Cardiac death
MYOCARDIAL INFARCTION (MI), SUDDEN DEATH, CARDIAC EVENTS, CARDIAC DEATH, MYOCARDIAL NECROSIS, SECONDARY, SAID, EVENTS, HEART FAILURE, CARDIAC DEATH
The primary endpoint of the study was the incidence of CA-AKI, which identifies events based on Improving Global Outcomes (KDIGO) serum creatinine criteria [increase in serum creatinine by ≥ 26.5 µmol/l (0.3 mg/dl) or increase in serum creatinine by ≥ 1.5 times baseline value]. AKI was said to be present if these changes occurred within 72 h from the initial contrast dose [The secondary endpoint was the occurrence of major adverse cardiac events (MACEs) including all-cause death, cardiac death, non-fatal myocardial infarction (MI), coronary revascularization, and cardiac rehospitalization. All-cause death was defined as the incidence of cardiac death or non-cardiac death. Cardiac death was defined as fatal MI and heart failure, sudden death, and other cardiac death. Non-fatal MI was defined as chest pain with new ST-segment changes and elevation of myocardial necrosis markers to at least twice the upper limit of the normal range. Coronary revascularization was defined as the revascularization of the target vessel or non-target vessels. Cardiac rehospitalization referred to rehospitalization for angina pectoris or heart failure.